Shire Makes Offer for Baxalta

Irish pharmaceutical producer Shire has made an offer to buy US drugmaker Baxalta for around $30 billion in stock. With the bid, Shire is said to be trying to solidify its position in rare disease treatments. Deerfield, Illinois-based Baxalta, spun off from Baxter International Inc. in July, specializes in bleeding disorders. 

Dublin-headquartered Shire makes treatments for a range of conditions including attention deficit hyperactivity disorder, epilepsy and hunter syndrome. It said the combination with Baxalta would create a global leader in rare disease drugs with $20 billion in sales by 2020.

In a statement dating from mid-July, Shire urged Baxalta to engage in negotiations. The company said it offer implies a value of $45.23 per share, a 36% premium.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.